Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Other neoplasm 1Myeloid 1

Conditions

Precancerous Conditions 55Multiple Myeloma 10Lymphoma 10Leukemia 10Neoplasms, Plasma Cell 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myeloproliferative Disorders 8Myelodysplastic Syndromes 8Monoclonal Gammopathy of Undetermined Significance 8Lymphoma, T-Cell, Cutaneous 8Lymphoma, Non-Hodgkin 8Lymphoma, Mantle-Cell 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Hodgkin Disease 8Burkitt Lymphoma 8Primary Myelofibrosis 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Myeloid, Acute 7Keratosis, Actinic 7Immunoblastic Lymphadenopathy 7Waldenstrom Macroglobulinemia 6Thrombocythemia, Essential 6Sezary Syndrome 6Mycosis Fungoides 6

Interventions

ruxolitinib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Preleukemia × Other neoplasm × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡